ARCUS BIOSCIENCES INC (RCUS) Stock Price & Overview
NYSE:RCUS • US03969F1093
Current stock price
The current stock price of RCUS is 25.13 USD. Today RCUS is down by -5.6%. In the past month the price increased by 17.1%. In the past year, price increased by 202.77%.
RCUS Key Statistics
- Market Cap
- 3.15B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.30
- Dividend Yield
- N/A
RCUS Stock Performance
RCUS Stock Chart
RCUS Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to RCUS. When comparing the yearly performance of all stocks, RCUS is one of the better performing stocks in the market, outperforming 96.45% of all stocks.
RCUS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RCUS. The financial health of RCUS is average, but there are quite some concerns on its profitability.
RCUS Earnings
On February 25, 2026 RCUS reported an EPS of -0.89 and a revenue of 33.00M. The company beat EPS expectations (14.97% surprise) and missed revenue expectations (-9.4% surprise).
RCUS Forecast & Estimates
18 analysts have analysed RCUS and the average price target is 34.88 USD. This implies a price increase of 38.81% is expected in the next year compared to the current price of 25.13.
For the next year, analysts expect an EPS growth of -21.68% and a revenue growth -62.57% for RCUS
RCUS Groups
Sector & Classification
RCUS Financial Highlights
Over the last trailing twelve months RCUS reported a non-GAAP Earnings per Share(EPS) of -3.3. The EPS decreased by -6.45% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.99% | ||
| ROE | -55.94% | ||
| Debt/Equity | 0.16 |
RCUS Ownership
RCUS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.55 | 355.432B | ||
| AMGN | AMGEN INC | 15.27 | 188.147B | ||
| GILD | GILEAD SCIENCES INC | 15.12 | 165.877B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.34 | 110.672B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.34 | 80.984B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.97 | 41.869B | ||
| INSM | INSMED INC | N/A | 31.046B | ||
| NTRA | NATERA INC | N/A | 28.508B | ||
| BIIB | BIOGEN INC | 11.65 | 27.573B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.65B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.6 | 25.108B | ||
| MRNA | MODERNA INC | N/A | 20.96B | ||
| INCY | INCYTE CORP | 12.33 | 19B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RCUS
Company Profile
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of immunotherapies. The company is headquartered in Hayward, California and currently employs 601 full-time employees. The company went IPO on 2018-03-15. The firm has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The firm has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The firm is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). The company is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Company Info
IPO: 2018-03-15
ARCUS BIOSCIENCES INC
3928 Point Eden Way
Hayward CALIFORNIA 94545 US
CEO: Terry Rosen
Employees: 601
Phone: 15106946200
ARCUS BIOSCIENCES INC / RCUS FAQ
What does ARCUS BIOSCIENCES INC do?
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of immunotherapies. The company is headquartered in Hayward, California and currently employs 601 full-time employees. The company went IPO on 2018-03-15. The firm has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The firm has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The firm is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). The company is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
What is the current price of RCUS stock?
The current stock price of RCUS is 25.13 USD. The price decreased by -5.6% in the last trading session.
Does ARCUS BIOSCIENCES INC pay dividends?
RCUS does not pay a dividend.
What is the ChartMill rating of ARCUS BIOSCIENCES INC stock?
RCUS has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of ARCUS BIOSCIENCES INC (RCUS)?
ARCUS BIOSCIENCES INC (RCUS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.3).
What is ARCUS BIOSCIENCES INC worth?
ARCUS BIOSCIENCES INC (RCUS) has a market capitalization of 3.15B USD. This makes RCUS a Mid Cap stock.
Can you provide the ownership details for RCUS stock?
You can find the ownership structure of ARCUS BIOSCIENCES INC (RCUS) on the Ownership tab.